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Abstract
Background: Mutations in leucine-rich repeat kinase 2 (LRRK2) contribute to both familial and idiopathic forms of
Parkinson’s disease (PD). Neuroinflammation is a key event in neurodegeneration and aging, and there is mounting
evidence of LRRK2 involvement in inflammatory pathways. In a previous study, we described an alteration of the
inflammatory response in dermal fibroblasts from PD patients expressing the G2019S and R1441G mutations in
LRRK2.
Methods: Taking advantage of cellular reprogramming, we generated induced pluripotent stem cell (iPSC) lines
and neurons thereafter, harboring LRRK2G2019S and LRRK2R1441G mutations. We used gene silencing and functional
reporter assays to characterize the effect of the mutations. We examined the temporal profile of TNFα-induced
changes in proteins of the NF-κB pathway and optimized western blot analysis to capture α-synuclein dynamics.
The effects of the mutations and interventions were analyzed by two-way ANOVA tests with respect to
corresponding controls.
Results: LRRK2 silencing decreased α-synuclein protein levels in mutated neurons and modified NF-κB transcriptional
targets, such as PTGS2 (COX-2) and TNFAIP3 (A20). We next tested whether NF-κB and α-synuclein pathways converged
and found that TNFα modulated α-synuclein levels, although we could not detect an effect of LRRK2 mutations, partly
because of the individual variability. Nevertheless, we confirmed NF-κB dysregulation in mutated neurons, as shown by
a protracted recovery of IκBα and a clear impairment in p65 nuclear translocation in the LRRK2 mutants.
Conclusions: Altogether, our results show that LRRK2 mutations affect α-synuclein regulation and impair NF-κB
canonical signaling in iPSC-derived neurons. TNFα modulated α-synuclein proteostasis but was not modified by the
LRRK2 mutations in this paradigm. These results strengthen the link between LRRK2 and the innate immunity system
underscoring the involvement of inflammatory pathways in the neurodegenerative process in PD.
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Background
Parkinson’s disease (PD) is a neurodegenerative disorder
characterized by a progressive and relatively selective
death of dopamine (DA) neurons within the substantia
nigra of the midbrain [1]. The neuropathological hall-
mark of PD is the Lewy body fibrillar aggregates in
which α-synuclein is the major constituent [2]. The great
majority of PD cases are sporadic, with only 5–10% be-
ing familial. Mutations in the leucine-rich repeat kinase
2 (LRRK2, PARK8) gene are the most common cause of
monogenic PD [3]. Furthermore, both common and un-
common variants are associated with an increase odd
risk in GWAS analyses [4]. The precise physiological
function of LRRK2 has yet to be defined due to its
involvement in multiple pathways, but we and others
have proposed an active role in the immune response
(reviewed in [5]). Indeed, in a previous study, we demon-
strated a defective NF-κB activation in response to a
pro-inflammatory stimulus in dermal fibroblasts from
PD patients [6]. NF-κB activation is responsible for the
intracellular regulation of age-related inflammation which
appears to play a major role in neurodegeneration.
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LRRK2 is a large multi-domain protein with two
enzymatic activities, a serine/threonine kinase and a
ROC (Ras of complex)-GTPase [3]. The G2019S sub-
stitution in the kinase activation loop is by far the
most common pathogenic mutation and increases the
kinase activity [7, 8]. The R1441G/C/H/S substitutions
in the ROC-GTPase domain generally result in lower
GTPase activity, with more inconsistent effects on kinase
activity [3]. Despite these differences, most pathogenic
mutants display an increase in the (auto)phosphorylation
at Ser1292 [9] and also in the phosphorylation of at least
one other substrate, the Rab GTPases [10]. Unraveling a
common mechanism for all LRRK2 mutations is critical
for understanding LRRK2 role in PD pathogenesis.
Increasing experimental evidence underscores the in-
volvement of LRRK2 in the inflammatory response, sup-
ported also by the robust LRRK2 expression in immune
cells, including peripheral monocytes and macrophages,
and in primary microglia (reviewed in [5]). The link to
the innate immune response is further reinforced by the
genetic association of LRRK2 with susceptibility to
inflammatory bowel disorder [11] and leprosy [12, 13].
Moreover, the expression of LRRK2 is modulated by
immune cell-specific signals, like IFNγ and toll-like
receptor (TLR) agonists [14–16].
In order to examine inflammatory responses in a
disease-relevant context, we extended our previous work
on patients’ fibroblasts harboring LRRK2G2019S and
LRRK2R1441G mutations by reprogramming the cells and
using neurons derived from the induced pluripotent
stem cells (iPSCs). In this cellular model, which pre-
serves the endogenous (and regulated) expression of
LRRK2, we examined the effect of the mutations on α-
synuclein and TNFα-induced NF-κB activation, with the
hypothesis that inflammatory stimuli can modulate α-
synuclein proteostasis.
Methods
Reprogramming and generation of iPSC lines
The experimental protocol was approved by the Ethical
Committee at Hospital Donostia (San Sebastian, Spain),
and all procedures adhered to the internal and EU guide-
lines for research involving derivation of pluripotent cell
lines. All subjects gave informed consent for the study
using forms approved by the Ethical Committee on the
Use of Human Subjects in Research at Hospital Donostia
and Onkologikoa Hospital, both in San Sebastian, Spain.
Generation of iPSC lines was approved by the Advisory
Committee for Human Tissue and Cell Donation and
Use, Instituto Carlos III (ISCIII), Madrid, Spain. All proce-
dures were done in accordance with institutional guide-
lines, and the cell lines have been deposited at the Banco
Nacional de Lineas Celulares (BNLC, ISCIII) following the
Spanish legislation.
Skin fibroblast cultures from PD patients with muta-
tions in LRRK2 and matched healthy subjects have been
previously characterized in our laboratory [6]. We
included samples from four men and two women, with a
median age of 62.5 ± 13.9 years. Dermal fibroblasts were
cultivated as described previously [6].
For this study, we reprogrammed fibroblasts from two
LRRK2G2019S and two LRRK2R1441G different patients. We
used lentiviral vectors containing c-Myc, Oct-4, Sox-2,
and Klf-4 as previously reported [17], and iPS cell lines
were characterized following standard procedures defined
by the BNLC in accordance with international guidelines.
Results for the two LRRK2R1441G (that have not been pre-
viously reported in the literature) are shown in Fig. 1.
Controls included a human embryonic stem cell line (H9)
to control for a possible effect of the lentiviral reprogram-
ming procedure and iPSC lines from healthy individuals,
previously generated in our laboratory [17].
Maintenance of iPSCs and differentiation to DA neurons
iPSCs were cultured and differentiated as described in
[17] with minor modifications. iPSCs were maintained on
irradiated human foreskin fibroblasts (HFF-1, SCRC-1041,
ATCC) in hES cell medium made of knockout-DMEM
(10829-018, Invitrogen), supplemented with 2 mM Gluta-
max (#3505003, Invitrogen), 50 nM β-mercaptoethanol
(31350-010, Invitrogen), 1× non-essential amino acids
(M7145, Sigma), 20% knockout serum (KSR10828028,
Invitrogen), 50 U/ml penicillin, 50 μg/ml streptomycin,
and 10 ng/ml FGF2 (100-18B, PeproTech). iPS cell
colonies were passaged manually once a week.
The protocol used for DA induction and differentiation is
shown schematically in Fig. 2a. Undifferentiated cells were
plated on Matrigel in hES cell medium (D0), and 1 day later
(D1), half of the hES cell medium was replaced with
DMEM-F12 supplemented with 1× N2 supplement
(#17502048, Invitrogen) and 10 ng/ml FGF2. Neural induc-
tion was started at D2 by adding 10 μM SB431542 (#1614,
Tocris) and 100 nM LDN-193189 (130-096-226, Miltenyi
Biotech). For the induction of DA phenotype, 500 nM SAG
(smoothen agonist, #566660, Millipore), and 0.5 nM CHIR
99021 (#13122, Cayman Chemical) were added to the
medium. On D12, neural rosettes were mechanically pas-
saged onto 0.1% gelatine (G1393; Sigma), 15 μg/ml polyor-
nithine, 1 μg/ml fibronectin, and 1 μg/ml laminin-coated
plates and expanded at high cell densities. At this time,
LDN and CHIR 99021 were removed from the medium;
SAG was reduced to 20 nM, and 100 ng/ml FGF8 was
added. At D14, the medium was also supplemented with
20 ng/ml BDNF and 200 μM ascorbic acid (BASF medium).
Subsequent passages of neural progenitors were done using
Accutase® (Sigma-Aldrich®). On ∼D20, BASF medium was
replaced with BCT-GA medium, composed of neurobasal
medium with 1× N2 supplement, 1× B27 supplement
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Fig. 1 Characterization of pluripotency of the LRRK2R1441G mutant iPSC lines (PD-R1 and PD-R4). a, b Reprogrammed cells formed compact uniform colonies
that showed robust and uniform expression of typical pluripotent markers such as NANOG and embryonic stage-specific antigen 4 (SSEA-4) by
immunofluorescence. Sequence analysis of exon 31 confirmed the presence of the point mutation in the clones selected for this study. c G-band karyotypes
for the selected clones. Pluripotency was confirmed d in vitro by embryoid body formation and trilineage differentiation, analyzed by immunofluorescence
and e in vivo by formation of teratomas in NOD-SCID mice that showed cells corresponding to the three germ layers. SMA smooth muscle actin, SAct sarco-
meric actin, AFP alpha fetoprotein, TUJ1 βIII-tubulin, TH tyrosine hydroxylase, H/E hematoxylin/eosin. Scale bars are indicated in each panel
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Fig. 2 (See legend on next page.)
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(17504-044, Invitrogen), 2 mM Glutamax, 20 ng/ml BDNF,
10 ng/ml GDNF, 200 μM ascorbic acid, 0.5 mM dibutyryl-
cAMP, 1 ng/ml TGF-β III, and 1 μg/ml laminin. As shown
in Fig. 2a, we defined three stages: induction stage, weeks
1–3 (D0–D20); expansion stage, weeks 4–5 (D28-D35); and
maturation stage, week 6–onwards (>D40). All the experi-
ments were carried out in the maturation stage.
To evaluate the NF-κB activity, cells were stimulated
by the addition of TNFα (#210-TA-005, R&D Systems),
with 10 and 15 ng/ml as indicated in the “Results”
section.
LRRK2 gene knockdown
Endogenous LRRK2 expression was silenced as previ-
ously described [6] using the MISSION® shLRRK2 vector
(TRCN0000358257, SIGMA) with a multiplicity of infec-
tion (MOI) of 8. As a control, cells were transduced with
the empty vector (mock control). The viral supernatant
was removed 18 h later and replaced with fresh growth
medium. The following experiments were carried out
5 days after transduction.
Western blotting
For whole-cell lysate preparation, neurons were har-
vested using Accutase®, washed in PBS and lysed in RIPA
lysis buffer (50 mM Tris-HCl pH 8, 150 mM NaCl,
1 mM EDTA, 1% NP-40, 0.1% SDS, 0.25% sodium deox-
ycholate) with 1 mM sodium orthovanadate, 1 mM NaF,
and a protease inhibitor cocktail (Roche). For probing α-
synuclein, the cells were washed with PBS and lysed in a
modified RIPA buffer (50 mM Tris-HCl pH 8, 150 mM
NaCl, 1 mM EDTA, 1% Triton X-100, 0.5% SDS, 0.5%
sodium deoxycholate, 5% glycerol). Lysates were briefly
sonicated, clarified by centrifugation at 15,000 rpm for
15 min and finally resolved by SDS-PAGE. Immunopre-
cipitation was performed using Protein-G cross-linked
with the anti-p62 antibody (P0067, Sigma). For the
kinetic experiments, the cells were stimulated with
TNFα, washed with PBS 1×, and lysed in SDS-PAGE
loading buffer (2% SDS, 5% 2-mercaptoethanol, 10% gly-
cerol, 0,1% bromophenol blue, 62.5 mM Tris-HCl, pH
6.8). After SDS-PAGE, the proteins were transferred to
polyvinylidene difluoride (PVDF) membrane (Immobilon-
P, Merck-Millipore). The following antibodies were used
at a 1:1000 dilution: LRRK2 (NB110-58771, Novus Biolog-
icals), p62 (P0067, Sigma), Sam68 (C-20, #sc-333, Santa
Cruz Biotechnology), IκBα (L35A5, #4814, Cell Signal-
ling), α-synuclein (MA1-12874, Thermo Scientific), Tau
(T46, #136400, Invitrogen), βIII-tubulin (mms-435p, Cov-
ance), and TH (P60101-0, Pel Freez Biologicals); α-tubulin
(DM1A, #3873, Cell Signalling Technology®) was used at
1:5000 dilution. A horseradish peroxidase-conjugated IgG
(GE Healthcare) was employed as a secondary antibody.
Visualization of HRP-labeled proteins was performed
using enzyme-linked chemiluminescence (ThermoFisher
Scientific) either detected on X-ray films or directly with a
digital CCD camera (Versadoc Imager, Bio-Rad). Bands
were quantified by densitometry relative to the corre-
sponding loading control using ImageJ (NIH).
Immunofluorescence
Cells cultured on sterile glass cover slips were fixed with
4% paraformaldehyde for 10 min at room temperature.
The cells were then permeabilized and blocked with 10%
donkey serum in 0.1% Triton X-100/PBS for 45 min. Pri-
mary antibody incubation was performed overnight at
4 °C, using the following antibodies diluted in PBS as in-
dicated: Nanog (1:100, R&D), SSEA-4 (1:100, Hybridoma
Bank, U.IOWA), SMA (1:400, Sigma), sarcomeric actin
(1:400, Sigma), AFP (1:400, DAKO), FOXA2 (1:100,
Santa Cruz Biotechnology), Nestin (1:500, Neuromics),
p65 (1:100, sc-372, Santa Cruz), TH (1:1000, P60101-0,
Pel Freez Biologicals), α-synuclein (1:100, MA1-12874,
Thermo Scientific), Tau (1:200, T46, #136400, Invitro-
gen), βIII-tubulin (1:1000, prb-435p-100, Covance),
NURR1 (1:200, E-20, sc-990, Santa Cruz), and GFAP
(1:500, Z0334, Dako). Next, the cells were washed with
10% donkey serum/PBS and incubated for 1 h with
Alexa fluorochrome-conjugated secondary antibodies
diluted in PBS. After final washes with 0.1× PBS, the
cover slips were mounted using ProLong® antifade
reagent (Molecular Probes®, Life Technologies). Images
were acquired with a Zeiss LSM510 confocal microscope
and analyzed using ImageJ (1.49, NIH). For quantification
(See figure on previous page.)
Fig. 2 Characterization of iPSC-derived DA neurons with LRRK2 mutations. a Diagram showing the DA differentiation protocol used for neural
induction of human iPSC lines. b Temporal gene expression analyzed by qRT-PCR at three time points: induction (3 weeks), expansion (4–5 weeks),
and maturation (>6 weeks). Each point represents the mean ± SEM of at least two independent differentiation experiments. c Representative
images of mature neuronal cultures showing expression of neuronal (βIII-tubulin, Tau, and α-synuclein) and dopaminergic (TH, NURR1) markers.
Nuclei were counterstained with Hoechst. Scale bars: 50 μm. d Quantification of immunostainings. Data are represented as mean ± SEM of counts from
at least two different lines for each genotype. e Representative western blot analyses of TH, Tau, and GFAP with βIII-tubulin as loading control in iPSC-
derived mature neurons. f Representative immunoblots and quantification of LRRK2 expression in mature neuronal cultures. α-tubulin was the loading
control and data were normalized to control WT neurons. Bars represent the mean ± SEM of at least two different lines per genotype. DIV days in vitro,
GEL gelatin, POL poly-ornithine, FBN fibronectin, LMN laminin, N2 N2 supplement, bFGF basic fibroblast growth factor, SAG smoothened agonist, LDN
LDN-193189, CHIR CHIR99021, SB SB431542, BDNF brain-derived neurotrophic factor, AA ascorbic acid, B27 B27 supplement, dbcAMP dibutyryl cyclic
adenosine monophosphate, TGFβIII transforming growth factor βIII, GDNF glial derived neurotrophic factor. See Additional file 2 for uncropped blots
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of neuronal markers, tile images (1272 × 1272 μm) were
acquired at a ×40 magnification and at least 1000 cells
were counted for each cell line. For the evaluation of
nuclear p65 translocation, images were randomly acquired
at ×63 magnification, and between 150 and 300 cells were
scored for each condition.
Real-time RT-PCR
Total RNA was extracted using Trizol® total RNA isolation
reagent (Gibco®, Life Technologies), followed by the
RNeasy Qiaprep (Qiagen) per manufacturer’s protocol.
RNA concentration was quantified using a NanoDrop
Spectrophotometer (NanoDrop Technologies). cDNA was
synthesized from total RNA using random hexamers
according to the GeneAmp® RNA PCR Core Kit (Life
Technologies) and the High-Capacity cDNA RT kit
(Applied Biosystems®, Life Technologies). Real-time
PCR was performed using an Applied Biosystems
StepOne™ Detection System. Comparative analysis of
gene expression levels (ΔΔCt) was carried out using
GAPDH as the reference gene. The sequences of the
primers are indicated in Additional file 1.
Luciferase assays
We used the Dual-Luciferase® Reporter (DLR™) Assay
System (Promega) to measure the activity of firefly and
Renilla luciferases sequentially from a single sample. We
used the pNF3ConA-Luc plasmid [6] and the pRL-CMV
(#E226A, Promega) for normalization of gene expres-
sion. Both plasmids were co-transfected into the neu-
rons by electroporation according to the standard
protocols (Neon® Transfection System, Invitrogen™, Life
Technologies). Briefly, one million cells were resus-
pended in 10 μl buffer R containing 1 μg pNF3ConA-
Luc, and 100 ng pRL-CMV were subjected to two pulses
(1000 V, 10 ms), and re-plated on 12-well plates. Forty-
eight hours later, neurons were treated with TNFα for
8 h in neurobasal medium without trophic factor supple-
mentation. Normalized data are expressed as the firefly
(NF-κB) divided by the Renilla luciferase activity.
Data transformation and analysis
Data were analyzed using Prism 4.0 (GraphPad Software).
All experiments were performed in at least two different
cell lines (from different individuals) for each genotype
and in at least two independent differentiations. Bar
graphs represent average and SEM. Values were normal-
ized as specified in the figure legends. Comparison
between groups was carried out by one-way ANOVA with
Dunn’s post-test (one variable) or two-way ANOVA with
Bonferroni post-test (two variables). Values of P < 0.05
were considered significant.
Results
Reprogramming and derivation of LRRK2 iPSC-derived DA
neuronal cultures
We generated iPSCs from four PD patients harboring
mutations in LRRK2. Two patients carried the G2019S
in the kinase domain of the protein and another two pa-
tients carried the R1441G mutation in the ROC-GTPase
domain (Fig. 1). Several reports have used LRRK2G2019S
and LRRK2R1441C iPSC lines, but this is the first study
describing iPS cell lines carrying the LRRK2R1441G muta-
tion. There was no effect of the mutations on the repro-
gramming process, and we obtained pluripotent cell
lines that maintained the original mutation, had normal
karyotypes, and had potential to generate the three
germ layers both in vitro and in vivo (Fig. 1a–e). Cell
lines generated for the study have been deposited in
the Spanish repository (BNLC) and are available at
http://www.isciii.es/ISCIII/es.
We next differentiated iPSCs towards a dopamine
phenotype, using a double-SMAD inhibition protocol,
illustrated in Fig. 2a. Neuronal markers were first
detected by qPCR during the expansion stage and
increased gradually with time (Fig. 2b). We analyzed the
expression profile of several PARK genes (LRRK2, SNCA,
PINK1). While SNCA and PINK1 levels increased stead-
ily, LRRK2 RNA levels were more variable along the dif-
ferentiation process but were not different between
groups. RNA levels of the glial marker GFAP were low
at all times examined (Fig. 2b).
Immunofluorescence analysis of neurons during the
maturation stage demonstrated that 90.4 ± 4.4% of
cells were βIII-tubulin-positive and 13.3 ± 6.4% of
βIII-tubulin-positive cells were TH-positive. Of these
TH-positive cells, 88.3 ± 5.5% co-expressed NURR1
(Fig. 2c, d). These in vitro generated neurons showed
a normal developmental expression of specific proteins like
the microtubule-associated protein Tau, which was present
in 73.5 ± 13.6% of cells in the cultures (Fig. 2c, d). Immuno-
blot analysis of protein extracts confirmed no differences in
either TH or Tau content across genotypes. Consistent with
the transcriptional profile, the glial marker GFAP was
barely detectable (Fig. 2e, Additional file 2). Importantly,
LRRK2 protein expression showed no differences between
genotypes at 6 weeks (Fig. 2f).
Taken all analyses together, we concluded that there
were no differences in the efficiency of neuronal specifi-
cation and markers’ expression in these cultures; the low
numbers of DA neurons that we obtained in these
experiments were not related to the presence of LRRK2
mutations.
LRRK2 regulates α-synuclein proteostasis
We analyzed the expression of monomeric soluble α-
synuclein in our differentiated neurons, since α-synuclein
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levels have been reported to be higher in LRRK2G2019S
neurons [18, 19].We confirmed that in LRRK2G2019S
cultures, α-synuclein levels were twofold higher than that
in the control wild-type (WT) cultures at the late stage of
differentiation (two-way ANOVA, P < 0.01, LRRK2G2019S
v. WT LRRK2, late stage) (Fig. 3a, Additional file 3). Inter-
estingly, from the point of view of age-related neurode-
generation, this phenotype was only observed in mature
neurons (two-way ANOVA, effect of time, P < 0.05). Also
notably, this appears to be quite specific for LRRK2G2019S
neurons, since α-synuclein levels were not increased in
the LRKK2R1441G neuronal cultures (Fig. 3a). The autoph-
agic mediator p62, implicated in the removal of α-
synuclein, has been reported to be increased in
LRRK2G2019S neurons [19]. However, we did not find any
differences in p62 basal levels in neurons with either
LRRK2 mutation at any stage (Fig. 3b).
To better define the role of LRRK2 in the regulation of
these proteins in neurons, we analyzed α-synuclein after
silencing endogenous LRRK2 expression. Analysis 5 days
after transduction showed an average decrease in LRRK2
RNA of 60 ± 10%, compared to mock-transduced cells,
and a corresponding decrease in LRRK2 protein levels
(Fig. 3c). The presence of mutations did not affect silen-
cing efficiency. LRRK2 knockdown significantly reduced
α-synuclein protein levels overall, and this effect was
driven by the marked decrease observed in the mutant
neurons (two-way ANOVA, P < 0.001; Bonferroni post-
test, P < 0.05 for both LRRK2G2019S and LRRK2R1441G)
(Fig. 3d). This result shows that mutations in LRRK2
affect α-synuclein regulation in neurons. Despite this
large effect on protein levels, SNCA RNA did not change
in LRRK2 silenced neurons, indicating that the regula-
tion is not taking place at the transcriptional level
(Fig. 3d). Therefore, we next examined p62 in LRRK2-
silenced neurons, and we did not observe changes in its
protein levels, concluding that LRRK2 modulation of α-
synuclein is independent of p62, at least in these condi-
tions (Fig. 3e).
Transcriptional effects of LRRK2
We have previously reported a strong effect of LRRK2
silencing on NF-κB target genes in fibroblasts [6]. There-
fore, we investigated the role of LRRK2 in the regulation
of this pathway in mature neurons. We found that
LRRK2 knockdown significantly affected PTGS2 (COX-
2), TNFAIP3 (A20), and TNFRSF1A (TNFR1) expression,
but not all to the same extent (Fig. 4a, c, e). While
shLRRK2 induced a decrease in TNFRSF1A in all geno-
types, TNFAIP3 RNA levels were reduced only in LRRK2
mutated neurons. We did not observe significant
changes in IL-6, NFKBIA (IκBa), and TNFRSF1B
(TNFR2) expression in silenced neurons of any genotype.
This indicates that LRRK2 knockdown does not affect
all NF-κB target genes equally because these are add-
itionally regulated in each specific cell context. Import-
antly, LRRK2 silencing did not modify the constitutively
expressed genes PTGS1 (COX-1) and βIII-tubulin (TUJ1)
(Fig. 4g, h). This confirms the lack of toxicity of LRRK2
silencing in mature human neurons and the specificity
of the changes observed. Taken together, these data
strengthen the link between LRRK2 and the NF-κB path-
way in neurons.
TNFα effect on α-synuclein protein levels
Our results so far confirmed a regulatory role of LRRK2
on α-synuclein proteostasis, as well as on NF-κB tran-
scriptional activity. Interestingly, there are several NF-κB
binding sites in the SNCA promoter, so we next investi-
gated the effect of NF-κB activation with TNFα on α-
synuclein levels in this paradigm. We treated mature
neurons with TNFα (15 ng/ml) for the times indicated in
the figure and observed a modulation of α-synuclein
protein levels (Fig. 5a, Additional file 4, RT-ANOVA,
effect of time, P < 0.05) with no significant effect of the
genotype. A parallel (but not significant) trend was
observed for p62 levels (Fig. 5b). The small, transient in-
creases after TNFα challenge in all neurons support our
hypothesis that inflammatory stimuli activating the
NFĸB pathway can modulate α-synuclein protein levels.
We next analyzed the interaction of α-synuclein with
the autophagic protein p62 in WT neurons but could
not detect any association between the two proteins in
differentiated neurons (Fig. 5c). Thus, it is unlikely that
modifications in α-synuclein in response to TNFα
involve p62 in these conditions.
Mutations in LRRK2 alter NF-κB activation
To examine the impact of LRRK2 mutations on NF-κB
function, we treated mature neurons with TNFα
(10 ng/ml, 8 h). In all the genotypes, basal NF-κB activ-
ity was similar and TNFα induced a significant NF-κB
response (two-way ANOVA, P < 0.01). However, while
the control WT cells showed a relatively large response
(tenfold, P < 0.05, Bonferroni post hoc test),
LRRK2G2019S and LRRK2R1441G neurons displayed a
more variable activation of smaller amplitude (≤4-fold,
n.s., Bonferroni post hoc test) (Fig. 6a).
Degradation of IκBα, which retains the NF-κB effector
dimer p65/p50 in the cytoplasm, is an essential event for
the activation of canonical NF-κB pathway following a
TNFα challenge (Fig. 6b). Time-course analysis of IκBα
levels showed a rapid degradation in response to TNFα
in all genotypes corroborating activation of the pathway
(two-way RT-ANOVA, effect of time, P < 0.0001). Quan-
tification of the area under the curve (AUC) revealed a
delay in the recovery of IκBα in the neurons with LRRK2
mutations (Fig. 6c, Additional file 5). During the
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degradation phase (0–0.5 h), the AUCs were 0.3620,
0.3874, and 0.3950 for the control WT, LRRK2G2019S,
and LRRK2R1441G neurons (C < G < R), respectively. In
contrast, during the recovery phase (1–8 h), the AUCs
were 5.936, 4.965, and 5.155 for the control WT,
LRRK2G2019S, and LRRK2R1441G neurons (C > R > G), re-
spectively. Indeed, 2 h after the TNFα stimulation, IκBα
levels were back to 80% of baseline in the control WT
neurons while in LRRK2 mutant neurons, the levels
reached only ~65% at this time. Moreover, neurons with
LRRK2 mutations failed to get back to the initial values
at the latest time examined (8 h). Interestingly, fibroblast
cultures from these patients displayed a delayed IκBα
recovery rate as well. However, in fibroblasts, IκBα levels
were back to baseline in all genotypes by 2 h (Fig. 6d),
suggesting that the NF-κB transcriptional defect associ-
ated with LRRK2 mutations is more pronounced in the
neurons.
We next evaluated p65 nuclear translocation in mature
neurons by IF at 0.5 and 2 h after TNFα stimulation
Fig. 3 LRRK2 regulation on α-synuclein levels. a Western blot analysis of basal α-synuclein and b p62 levels in neurons during mid and late differentiations.
Blots show the α-synuclein soluble monomer of ~15 kDa. Bars represent the mean ± SEM of three to six values, including two different cell lines per group.
βIII-tubulin was used as loading control (two-way ANOVA, ** P< 0.01, LRRK2G2019S v. control WT, late stage). c LRRK2 RNA levels 5 days after shRNA lentiviral
transduction. The empty vector was used as the mock control. Lines represent the mean ± SEM of three to four independent silencing experiments. A
representative immunoblot analysis of LRRK2 protein levels 5 days after transduction is also shown. βIII-tubulin was the loading control. d Immunoblots
and corresponding quantification of α-synuclein 5 days after shLRRK2 transduction. Bars represent the mean ± SEM of at least three independent silencing
experiments. LRRK2 silencing had a significant effect on α-synuclein protein levels (two-way ANOVA, *** P= 0.0002). Bonferroni post hoc test showed that
this effect was limited to LRRK2 mutated mature neurons (**P< 0.05 for both LRRK2G2019S and LRRK2R1441G). e qRT-PCR analysis of SNCA after LRRK2
silencing. f Immunoblots and corresponding quantification of p62 5 days after shLRRK2 transduction. Bars represent the mean ± SEM of at least three
independent silencing experiments. See Additional file 3 for uncropped blots
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(15 ng/ml). These time points were chosen to coincide
with the IκBα degradation and recovery phases observed
by western blot. Notably, already at baseline, LRRK2G2019S
and LRRK2R1441G cultures had a higher percentage of cells
displaying a clear nuclear p65 signal (Fig. 6e, f ) (0.8 ± 0.4,
3.6 ± 1.6, and 4.7 ± 1.8 in the control WT, LRRK2G2019S,
and LRRK2R1441G, respectively). TNFα induced an
increase in p65 nuclear localization in the control WTcul-
tures (50- and 53-fold over non-stimulated baseline at 0.5
and 2 h, respectively). This response to TNFα was slower
and significantly attenuated in all LRRK2 mutated neurons
(8 and 11.5 at 0.5 and 2 h in LRRK2G2019S; 6.2 and 5.8 at
0.5 and 2 h in LRRK2R1441G, two-way ANOVA, F = 24.68,
P < 0.001) (Fig. 6e, g). These results show that neurons
with LRRK2G2019S and LRRK2R1441G mutations have a
defect in p65 translocation underlying the protracted NF-
κB transcriptional response, similar to the defect that we
described before in patients’ fibroblasts [6].
Discussion
Taking advantage of iPSC technology, we investigated
NF-κB signaling in patient-specific neurons harboring
Fig. 4 Effect of endogenous LRRK2 silencing on NF-κB target genes. a-h qRT-PCR analyses of inflammatory genes 5 days after LRRK2 silencing. The effect
of LRRK2 silencing was evident in the regulation of RNA levels of COX-2, A20, and TNFR1. For COX-2, the effect of LRRK2 silencing was significant (two-way
ANOVA, ** P= 0.0021,), and post hoc analyses revealed a significant effect of shLRRK2 on RNA levels specifically in LRRK2G2019S neurons (** P< 0.01). For
A20, in addition to the effect of knocking down the expression of LRRK2 (two-way ANOVA, P < 0.0001), the presence of the mutations had also
a significant effect (two-way ANOVA, ** P = 0.008). Subsequently, there was an interaction between shLRRK2 and genotype (two-way ANOVA,
** P = 0.008). Indeed, post hoc analyses showed that there was an effect of LRRK2 silencing on A20 levels in LRRK2G2010 (*** P < 0.001) and
LRRK2R1441G neurons (** P < 0.01). Finally, for TNFR1, the effect of LRRK2 silencing was significant in all groups (two-way ANOVA *** P < 0.0001;
post hoc tests: *** P < 0.001 in Control WT and LRRK2G2019S and ** P < 0.01 in LRRK2R1441G). Mock cells were transduced with the empty vector.
Lines represent the mean ± SEM of three to five independent silencing experiments
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the G2019S and R1441G mutations in LRRK2. Some
LRRK2G2019S, LRRK2R1441C, and LRRK2I2020T iPSC
lines have been previously established and characterized
[19–27]. For this study, we derived two novel iPSC lines
with the R1441G substitution, which is frequent in the
Basque Country, in addition to two G2019S-iPSC lines.
Reprogramming and differentiation into DA neurons
was similar in all mutant lines. The efficiency of DA
neuronal specification, rather limited in this study, was
nonetheless comparable to that obtained from a hES cell
line (H9) and to that reported in other studies [19–27].
With this small percentage of DA neurons, our results are
Fig. 5 Effect of TNFα on α-synuclein. a Western blot analysis showing α-synuclein and b p62 proteins in mature neurons after treatment with
TNFα, at 2 and 6 h. Proteins were resolved in 15% SDS polyacrylamide gels for the visualization of different α-synuclein oligomers. The band at
15 kDa corresponds to the monomer. A band at 50 kDa (asterisk) could correspond to an oligomeric form of α-synuclein. α-tubulin was used as
loading control. Statistical analysis showed a significant effect of time on α-synuclein monomer levels in three to six independent experiments,
including two different cell lines per genotype (RT-ANOVA, effect of time, P = 0.035). c Control WT neurons were stimulated with TNFα and
with IL-1β to evaluate the interaction between p62 and α-synuclein. Co-immunoprecipitation of p62 and α-synuclein using specific antibodies
did not show any association under these conditions. Sam68 was used as the loading control. NS non-stimulated, IP immunoprecipitation, FT
flow-through. See Additional file 4 for uncropped blots
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Fig. 6 (See legend on next page.)
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better viewed as representative of a mature heterogeneous
neuronal population. Importantly, all experiments were
carried out at 6 weeks or later, when cultures mainly con-
tained mature neurons (90% of all cells) with normal Tau
expression levels and distribution. We could not detect
LRRK2 during the neural induction stage (1–3 weeks), but
protein expression increased at later stages following a
normal developmental profile [28, 29]. LRRK2 protein
levels were similar in all genotypes and, in agreement with
previous reports, LRRK2 endogenous baseline expression
was not increased in LRRK2G2019S neurons [19, 20]. This
is in stark contrast with overexpression studies that have
proposed an increased dimerization and protein stability
related to the mutation effect on kinase activity [25, 30].
For LRRK2I2020T and LRRK2R1441C, the stability of the pro-
tein has been reported to be impaired [27, 31].
There is overwhelming genetic and pathological evi-
dence for the involvement of α-synuclein in PD. In-
deed, missense mutations and multiplications in
SNCA [32–35] cause familial autosomal dominant
forms of PD. α-synuclein is also the main component of
the proteinaceous inclusions (Lewy bodies and neurites)
considered the pathological hallmark of PD [2, 36]. Fur-
thermore, α-synuclein propagation has been proposed to
underlie disease progression in a prion-like spreading
manner, although this is debatable [37]. In agreement with
previous studies in iPSC-derived neurons, we found ele-
vated levels of α-synuclein in LRRK2G2019S neurons at the
mature stage [18, 19, 22]. In contrast, α-synuclein was not
increased in the LRRK2R1441G neurons. This difference
can be related to the unequal effect of the two mutations
on LRRK2 kinase activity because only the G2019S muta-
tion robustly increases it [8]. Indeed, a recent paper
further supports the hypothesis of a direct link between
the enhanced kinase activity in the LRRK2G2019S neurons
and the increase in α-synuclein levels (and subsequent for-
mation of inclusions), as both LRRK2 specific kinase in-
hibitors and α-synuclein knockdown prevented inclusion
formation in mutants, in vitro and in vivo [38]. In our
study, LRRK2 silencing decreased α-synuclein expression
in human LRRK2 mutated neurons, underscoring the
tight connection between these two PARK gene products.
Importantly, we found that TNFα modulates α-synuclein
dynamics in iPSC-derived neurons. Other studies have
shown that TNFα and TLR activation in neurons increase
α-synuclein levels by inhibiting autophagy [39, 40]. In this
study, TNFα transiently increased α-synuclein levels, which
could eventually favor protein aggregation and pathogen-
icity [41, 42]. Unfortunately, because of the small magni-
tude of the changes, inter-individual differences and
technical limitations, we cannot discuss here the effect of
the LRRK2 mutations on different alpha-synuclein molecu-
lar forms, which could be relevant for disease pathogenesis
and deserves further work.
Wild-type LRRK2 has been proposed to activate in-
flammatory signaling. Overexpression of LRRK2 in vitro
up-regulated the canonical NF-κB pathway [14, 16, 43,
44], while the effect of PD-associated LRRK2 mutations
is less clear [14, 43]. Similarly, there is no consensus on
the role of LRRK2 kinase activity on the stimulation of
the NF-κB cascade [14–16, 44–46]. Discrepancies may
be partly due to the use of different cellular systems and
stimulation conditions and, in the case of LRRK2 inhibi-
tors, to off-target effects. On the other hand, knockdown
experiments of endogenous LRRK2 expression in pri-
mary microglia and immortalized immune cell lines
down-regulated inflammatory signaling, even in the ab-
sence of a pro-inflammatory stimulus [14, 15, 44, 45],
which is also in agreement with our findings in LRRK2-
silenced fibroblasts [6]. In neurons, we found a differen-
tial regulation of NF-κB transcriptional targets, which
may be dependent on cell-specific factors. Importantly,
we could identify a significant effect on COX-2, validat-
ing our previous findings in fibroblasts and underscoring
the preservation of the phenotype regarding the NF-κB
pathway in these and other experimental models [6, 47].
From a practical point of view, this is rather convenient as
dermal fibroblasts are easily accessible and expandable
and can be used to screen for disease modifiers regarding
this pathway. Nevertheless, neurons allowed us to explore
(See figure on previous page.)
Fig. 6 TNFα-induced NF-κB activation in neurons derived from iPSCs with LRRK2 mutations. a TNFα (10 ng/ml, 8 h) induced a significant NF-κB
activation (two-way ANOVA, ** P < 0.01) but only in control WT neurons (* P < 0.05, post hoc test) and not in LRRK2G2019S or LRRK2R1441G neurons (n.s.).
Bars represent the mean ± SEM of two to four determinations, including two different lines per genotype and expressed as fold values over untreated.
In addition, basal NF-κB activities are normalized to the activity in the control WT neurons. b Schematic representation of NF-κB pathway activation. c
Time-course of IκBα protein levels after treatment with TNFα (10 ng/ml). Immunoblots were quantified and normalized to non-stimulated (NS) samples.
Each point in the curve is the mean ± SEM of four to five independent experiments, including two different cell lines per genotype. α-tubulin was used
as the loading control. Statistical analysis showed a significant effect of time on IκBα protein levels (two-way RT-ANOVA, *** P < 0.0001). d For compari-
son, the same experiment is shown in fibroblasts. Points represent the mean ± SEM of three to six independent experiments, including at least two dif-
ferent cell lines per genotype. Sam68 was used as the loading control. Statistical analysis showed a significant effect of time on IκBα protein levels
(two-way ANOVA, *** P < 0.0001). e Representative immunofluorescence staining of p65 (green) and βIII-tubulin (blue) in mature neuronal cultures incu-
bated with TNFα (15 ng/ml, 0.5 and 2 h). Nuclei were counterstained with Hoechst 33342 (red). Scale bar, 20 μm. f Quantification of p65 immunoreac-
tivity at baseline and g after TNFα incubation showing a significant effect of genotype (two-way ANOVA, *** P < 0.001). Bars represent the mean ± SEM
of counts from two different lines per group in two to three independent experiments. NS non-stimulated. See Additional file 5 for uncropped blots
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neuronal specific proteins (such as α-synuclein) and
pathways.
The low endogenous expression of LRRK2 in iPSC-
derived neurons and the heterogeneous nature of the
cultures resulted in relatively small TNFα-induced NF-
κB response. Still, it was sufficient to detect the reduc-
tion in NF-κB transcriptional activation in response to
TNFα in both LRRK2G2019S and LRRK2R1441G neuronal
cultures. Furthermore, the recovery of IκBα protein,
which is a direct transcriptional product providing feed-
back pathway regulation, was also impaired in mutant
neurons. Given that IκBα degradation in the mutants
was normal, our data pointed to a defect downstream
p65 release from IκBα. Indeed, p65 nuclear translocation
was defective in LRRK2 mutants. In addition, LRRK2
mutated neurons displayed slightly increased levels of
nuclear p65 in the absence of any stimulus, supporting a
leaky regulation of the system. These defects in iPSC-
derived neurons corroborate our previous observations
in patients’ fibroblasts, albeit with minor differences.
Mechanistically, our results imply that both the
G2019S and R1441G mutations impair canonical NF-κB
signaling at the level of p65 nuclear translocation and/or
downstream transcriptional activation. Indeed, in LRRK2
mutant neurons primed with TNFα, IκBα degradation
was normal like in LRRK2-silenced microglia treated
with LPS [44]. p65 nuclear translocation may require
LRRK2 scaffold function, perhaps through interaction
with 14-3-3 proteins that could be disrupted by LRRK2
mutations [48–50]. On the other hand, mutations could
alter this pathway at other levels, like the DNA-binding
capacity of the transcription factor. In line with this,
recent reports described higher levels of the phosphory-
lated form of the NF-κB inhibitory subunit p50 in
LRRK2-silenced microglia, which correlated with subse-
quent higher p50 binding to DNA and transcriptional
repression [45]. It would be very informative to
characterize this response in neurons from sporadic PD
patients.
Conclusions
These results validate in neurons our previous findings
in patients’ fibroblasts regarding NF-κB signaling
modulation by LRRK2 and underscore the usefulness of
the iPSC-neuron paradigm to study time-dependent,
neuron-specific alterations in a context that retains
endogenous expression of pathogenic proteins. iPSC-
derived neurons carrying the G2019S and R1441G
mutations in LRRK2 showed impaired canonical NF-κB
signaling and altered NF-κB target gene transcription
regulation upon LRRK2 knockdown. Temporal analysis
following a TNFα challenge revealed a protracted
recovery of IκBα protein, concomitant with defective
p65 nuclear translocation in both LRRK2G2019S and
LRRK2R1441G neurons. Although basal α-synuclein pro-
tein levels were increased in LRRK2G2019S mature
neurons, and not in LRRK2R1441G neurons, LRRK2 si-
lencing down-regulated α-synuclein protein expression
in both. This led us to hypothesize that NF-κB and α-
synuclein pathways driving PD progression might con-
verge. Indeed, TNFα elevated α-synuclein levels,
although we could not detect an effect of LRRK2 muta-
tions. Further studies are needed to understand how
long-term neuroinflammation impacts on α-synuclein
dynamics and the contribution of LRRK2 mutations to
this pathway.
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